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Abstract 
Aims: Secreted frizzled‑related protein (Sfrp)5 has beneficial effects on insulin sensitivity, inflammation and cardio‑
vascular risk in different mouse models, but its relevance for cardiometabolic diseases in humans is controversial. 
We aimed to characterise associations of circulating SFRP5 with cardiometabolic risk factors and prediabetes/type 2 
diabetes in a large population‑based cohort.
Methods: Cross‑sectional associations between serum SFRP5 and cardiometabolic risk factors as well as prediabetes/
type 2 diabetes were investigated in 1096 participants aged 62–81 years from the German KORA F4 study, of whom 
666 had prediabetes or type 2 diabetes. Multivariable linear regression models were adjusted for potential confound‑
ers including age, sex, body mass index (BMI), lifestyle factors, lipids, hypertension, kidney function and myocardial 
infarction.
Results: Higher serum SFRP5 levels were associated with lower HbA1c, BMI, systolic blood pressure, estimated glo‑
merular filtration rate and high‑sensitivity C‑reactive protein levels and with higher levels of high‑density lipoprotein 
cholesterol and adiponectin in the fully adjusted model (all P < 0.009). In contrast, favourable associations between 
SFRP5 and glycaemia, insulin, insulin resistance and other cardiometabolic risk factors were attenuated after adjust‑
ment for BMI. Serum SFRP5 levels were lower in participants with prediabetes or type 2 diabetes [(median (25th; 75th 
percentile) 48.8 (35.5; 65.7) ng/ml] compared to participants with normal glucose tolerance [55.9 (42.6; 69.6) ng/ml] 
(P < 0.001). In the fully adjusted model, higher SFRP5 was associated with lower odds of prediabetes/type 2 diabetes 
[OR (95% CI) (0.72 (0.58; 0.89)) per doubling of SFRP5, P < 0.01].
Conclusions: Higher serum SFRP5 was inversely associated with multiple risk factors for type 2 diabetes and car‑
diovascular diseases. However, BMI represents a strong confounder of some of these associations. Higher circulating 
SFRP5 was also associated with lower odds of prediabetes/type 2 diabetes, and this association was independent of 
BMI. Thus, SFRP5 emerges as novel biomarker that merits further research in the context of prevention of cardiometa‑
bolic diseases.
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Background
The secreted frizzled-related protein 5 (SFRP5) belongs 
to the SFRP family, which comprises five members in 
humans, SFRP1-5, and is the largest family of Wnt inhibi-
tors [1]. However, SFRPs also antagonise one another´s 
activity, are able to bind to Frizzled receptors and interact 
with molecules outside of the Wnt signaling pathway [1]. 
SFRP5 is a secreted protein which is produced by several 
tissues such as visceral, subcutaneous and pericardial 
adipose tissue, liver, heart, mononuclear blood cells and 
pancreatic islets [2–8].
Obese mice lacking Sfrp5 have impaired glucose clear-
ance and reduced insulin sensitivity. Moreover, these 
mice are characterised by an increased content of mac-
rophages and pro-inflammatory proteins in adipose tis-
sue [9]. In mice that underwent ischaemia reperfusion 
injury, Sfrp5 mRNA was reduced in pericardial adipose 
tissue. The knockout of Sfrp5 in mice led to an increased 
size of myocardial infarction, a higher myocyte apopto-
sis rate and enhanced mRNA levels of pro-inflammatory 
proteins in the ischaemic area [8].
In humans, data on SFRP5 and cardiometabolic dis-
eases are controversial. Cross-sectional studies includ-
ing people with and/or without type 2 diabetes found 
that circulating SFRP5 showed a positive [10], an inverse 
[11–13] or no association [14] with insulin resistance. In 
two hospital-based studies serum SFRP5 was inversely 
associated with the metabolic syndrome and the severity 
of coronary artery disease [13, 15]. However, data from 
population-based studies on SFRP5 and cardiometabolic 
risk are currently not available.
Therefore, this study aimed (a) to characterise the asso-
ciations of serum SFRP5 levels with cardiometabolic risk 
factors, (b) to determine the relationship between SFRP5 
and the odds of prediabetes/type 2 diabetes, and (c) to 
investigate to what extent these associations were inde-
pendent of obesity and other potential confounders.
Study participants and methods
Study population
The study is based on data from the Cooperative Health 
Research in the Region of Augsburg (KORA) F4 study 
(2006–2008), a follow-up examination of the popula-
tion-based KORA S4 study (1999–2001) conducted in 
Augsburg (Germany) and two surrounding counties. The 
design of the KORA studies has been described before 
[16, 17]. Briefly, study participants were invited from the 
city of Augsburg and two adjacent counties based on the 
survey sampling method of the former World Health 
Organisation Monitoring of Trends and Determinants of 
Cardiovascular Disease (WHO MONICA) project [17]. 
Within each selected community in the study area, age 
and sex-stratified samples were drawn with four of these 
strata including men and women aged 55–74 years. This 
cross-sectional analysis uses data from all study partici-
pants between 62 and 81  years of age in the KORA F4 
study (n =  1161). Additional file  1: Figure S1 provides 
an overview of the study design, and Additional file  1: 
Table S1 compares participants and non-participants in 
KORA F4. In our analysis of the KORA F4 study sample, 
we excluded persons with unclear glucose tolerance sta-
tus due to missing values for fasting and/or 2-h glucose 
(n = 33), type 1 diabetes (n = 2), drug-induced diabetes 
(n = 1) or other missing covariables (n = 29), resulting in 
a sample size of 1096 individuals.
Anthropometric measurements
Height, body weight, waist circumference, systolic and 
diastolic blood pressure were measured as described 
[16, 17]. Body mass index (BMI) was calculated as body 
weight (kg)/[height (m)]2. Actual hypertension was 
defined as blood pressure of 140/90 mmHg or higher, or 
use of antihypertensive medication given that the study 
participants were aware of being hypertensive.
Assessment of glucose tolerance and diabetes status
Known type 2 diabetes was defined as self-report of a 
previous diagnosis of type 2 diabetes that could be vali-
dated by the responsible physician, or as current use of 
glucose-lowering agents. All study participants with-
out known type 2 diabetes were assigned to a standard 
75-g oral glucose tolerance test (OGTT). Glucose toler-
ance categories were defined using fasting and 2-h glu-
cose concentrations according to criteria of the American 
Diabetes Association [18]. Prediabetes was defined as 
impaired fasting glucose (IFG), impaired glucose toler-
ance (IGT) or combined IFG/IGT.
Glucose and insulin levels and HbA1c were meas-
ured as previously described [19]. Insulin sensitivity was 
assessed by calculation of the homeostasis model assess-
ment of insulin resistance (HOMA-IR) based on fasting 
glucose and insulin levels and the whole-body insulin 
sensitivity index (ISI [composite]) based on both fast-
ing and 2-h levels of glucose and insulin [19–21]. Fasting 
beta-cell function was estimated using HOMA-β [20].
Assessment of further metabolic, lifestyle 
and immunological variables
Serum lipid levels were measured as described [19]. Kid-
ney function was assessed from the estimated glomeru-
lar filtration rate (eGFR) using the chronic kidney disease 
epidemiology (CKD-EPI) creatinine equation [22, 23].
Trained medical interviewers collected information on 
medical history, physical activity, smoking, alcohol con-
sumption and use of medication [16]. Study participants 
were classified as physically active if they reported >1 h 
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of physical activity per week during leisure time in either 
summer or winter. Smoking status was defined as never, 
former or current smoking. Alcohol consumption was 
classified as none, moderate or high for an alcohol intake 
of 0, 0.1–39.9 or  ≥40  g/day for men and 0, 0.1–19.9 
or ≥20 g/day for women, respectively.
Plasma levels of high-sensitivity C-reactive protein 
(hsCRP) and serum levels of interleukin (IL)-6, IL-1 
receptor antagonist (IL-1RA) and total adiponectin were 
measured as described [24].
Quantification of SFRP5 serum levels
SFRP5 levels were measured in serum samples between 
08/2016 and 09/2016 that had been continuously stored 
at −80  °C between blood sampling and analysis. Meas-
urements were carried out using the Enzyme-linked 
Immunosorbent Assay Kit for Secreted Frizzled Related 
protein 5 (SFRP5) from Cloud-Clone (Houston, TX; 
previously USCN, Wuhan, China). The limit of detec-
tion (LOD) was 1.56  ng/ml. All sera yielded SFRP5 lev-
els above the LOD. Coefficients of variation (CV) were 
assessed using three control sera measured in duplicates 
on 16 plates. Mean intra- and inter-assay CV were 6.4 
and 18.6%, respectively.
Statistical analysis
Characteristics of the study population are given strati-
fied by quarters of serum SFRP5 and with age and sex-
adjusted P values from linear regression analysis for 
associations between SFRP5 and these characteristics.
Cross-sectional associations between  log2(SFRP5) and 
cardiometabolic risk factors were estimated by multivari-
able linear regression analysis using the following prede-
fined set of potential confounders from previous KORA 
analyses [19, 25]:
  • Model 1, adjusted for age and sex.
  • Model 2, model 1  +  smoking status (current/for-
mer/never), alcohol consumption, physical activity 
(active/inactive).
  • Model 3, model 2 + BMI.
  • Model 4, model 3  +  hypertension (yes/no), HDL 
cholesterol, LDL cholesterol, triglycerides, lipid-
lowering medication (yes/no), prevalent myocardial 
infarction (yes/no), eGFR.
Age, alcohol consumption, BMI, HDL cholesterol, LDL 
cholesterol, triglycerides and eGFR entered the models as 
continuous variables. In a sensitivity analysis, we replaced 
BMI with waist circumference in models 3 and 4.
Associations of  log2 (SFRP5) with prediabetes/diabetes 
or separate glucose tolerance status groups were assessed 
by logistic and multinomial logistic regression analysis, 
respectively, with individuals with normal glucose toler-
ance as reference group adjusting for the aforementioned 
covariables.
Associations between HbA1c, time since diabetes diag-
nosis and glucose-lowering medication and  log2 (SFRP5) 
were also estimated using linear regression analyses.
We checked the degree of multicollinearity in all mod-
els by calculating the variance inflation factors (VIF). 
Multicollinearity is considered high for VIF > 10, but VIF 
were <1.7 in all analyses.
All statistical analyses were performed with R ver-
sion 3.3.3 (R Core Team, R Foundation for Statistical 
Computing, Vienna, Austria) and Python version 3.6.1 
(Python Software Foundation, https://www.python.org/). 
A P value  <0.05 was considered to indicate statistical 
significance.
Results
Additional file  1: Table S1 gives a brief comparison of 
participants (n =  1161) and non-participants (n =  492) 
in the KORA F4 study. Non-participants were older and 
had higher systolic blood pressure and triglyceride levels, 
but did not differ in sex distribution, BMI, HbA1c, dias-
tolic blood pressure and cholesterol levels.
Table  1 shows the characteristics of the study popu-
lation after the exclusions described above (n  =  1096) 
stratified by quarters of SFRP5 serum levels. Higher 
SFRP5 levels were associated with higher age, whereas 
no association with sex was observed. After initial adjust-
ment for age and sex, higher SFRP5 levels were related to 
a more favourable cardiometabolic risk profile as evident 
by lower BMI and waist circumference, lower levels of 
fasting and 2-h glucose and insulin, lower HbA1c, higher 
insulin sensitivity and better glucose tolerance. Higher 
SFRP5 levels were also associated with lower systolic 
and diastolic blood pressure, higher HDL cholesterol, 
lower triglycerides, lower levels of biomarkers of sub-
clinical inflammation (hsCRP, IL-6, IL-1RA) and higher 
adiponectin levels. No associations were found between 
SFRP5 and fasting beta-cell function, the prevalence 
of hypertension, LDL cholesterol, use of lipid-lowering 
drugs, smoking, physical activity and alcohol consump-
tion. However, higher SFRP5 levels were associated with 
decreased eGFR.
Multivariable linear regression analyses showed that 
the aformentioned associations between SFRP5 levels 
and cardiometabolic risk factors (Tables 1 and 2, model 1) 
were largely unaffected by adjustment for lifestyle factors 
(physical activity, smoking, alcohol consumption; model 
2). Further adjustment for BMI (model 3) attenuated or 
even abolished most of these associations, whereas addi-
tional adjustment for metabolic factors (HDL cholesterol, 
LDL cholesterol, triglycerides, lipid-lowering medication, 
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Table 1 Description of the KORA F4 study population stratified by quarters of SFRP5 serum concentrations
Variable Quarter 1 Quarter 2 Quarter 3 Quarter 4 P
n 274 274 274 274
SFRP5 (ng/ml) 29.48 (23.88; 33.71) 44.54 (41.02; 48.23) 58.92 (55.58; 63.24) 79.78 (72.17; 89.54) <0.001
Age (years) 69.7 ± 5.1 70.3 ± 5.4 69.7 ± 5.3 71.2 ± 5.7 0.001
Sex (% male) 45.3 56.6 53.3 50.7 0.281
BMI (kg/m2) 30.6 ± 4.6 29 ± 4.3 28.1 ± 4.2 27.3 ± 4.0 <0.001
Waist circumference 
(cm)
102.2 ± 12.4 99.4 ± 12.0 97.3 ± 12.2 94.6 ± 11.1 <0.001
Fasting glucose 
(mmol/l)a
5.6 ± 0.6 5.6 ± 0.9 5.4 ± 0.6 5.4 ± 0.6 <0.001
2‑h glucose (mmol/l)a 7.5 ± 2.2 7.2 ± 2.4 6.8 ± 2.1 7.1 ± 2.4 0.002
HbA1c (%)a 5.68 ± 0.37 5.66 ± 0.51 5.60 ± 0.33 5.55 ± 0.35 <0.001
Fasting insulin (µU/
ml)a,b
6.0 (4.2; 10.4) 5.0 (3.3; 8.8) 4.6 (3.2; 7.5) 4.6 (3.0; 7.4) 0.007
2‑h insulin (µU/ml)a,b 65.7 (38.3; 105.9) 57.2 (33.7; 91.2) 50.0 (28.2; 77.7) 49.1 (25.1; 82.5) 0.001




12.74 (8.01; 22.52) 16.77 (9.22; 25.63) 18.74 (11.18; 29.59) 18.64 (10.41; 35.77) <0.001





29.2/19.7/12.8/12.4/6.2/19.7 34.7/23.7/9.9/10.9/5.8/15.0 48.9/15.7/7.3/11.3/5.1/11.7 44.2/16.1/9.9/10.2/9.1/10.6 <0.001
Systolic blood pressure 
(mmHg)c
131.3 ± 17.6 130.2 ± 15.9 128 ± 19.5 125.4 ± 20.8 <0.001
Diastolic blood pres‑
sure (mmHg)c
76.8 ± 9.4 76.8 ± 8.8 75.7 ± 9.8 74.0 ± 9.4 0.009
Hypertension (%) 61.7 64.2 60.6 63.9 0.782
LDL cholesterol 
(mmol/l)d
3.81 ± 0.86 3.78 ± 0.87 3.84 ± 0.96 3.75 ± 0.89 0.334
HDL cholesterol 
(mmol/l)d
1.4 ± 0.38 1.42 ± 0.35 1.45 ± 0.35 1.53 ± 0.40 <0.001
Triglycerides 
(mmol/l)b,d
1.36 (0.92; 1.89) 1.25 (0.98; 1.80) 1.27 (0.95; 1.72) 1.23 (0.89; 1.64) 0.026
Use of lipid‑lowering 
drugs (%)
22.6 25.5 24.1 25.7 0.373
eGFR (ml/min per 
1.73 m2)
78.9 ± 13.0 77.5 ± 14.9 76.8 ± 14.9 72.4 ± 16.4 <0.001
Smoking (never/for‑
mer/current) (%)
49.3/43.4/7.3 49.3/42.0/8.8 46.0/46.0/8.0 50.7/43.1/6.2 0.992




36.5/53.6/9.9 27.4/62.4/10.2 33.9/56.9/9.1 29.9/61.3/8.8 0.170
hs C‑reactive protein 
(mg/l)b
2.25 (1.04; 4.38) 1.46 (0.89; 2.91) 1.38 (0.75; 2.82) 1.39 (0.62; 2.75) <0.001
IL‑6 (pg/ml)b 1.81 (1.21; 2.67) 1.63 (1.17; 2.45) 1.57 (1.08; 2.34) 1.52 (0.98; 2.26) 0.001
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Data are given as mean ± SD, median and 25th; 75th percentiles or percentages, unless indicated otherwise. P values are adjusted for age and sex using linear 
regression analysis. The analysis for age is adjusted for sex only, the analysis for sex is adjusted for age only
eGFR estimated glomerular filtration rate, HDL high‑density lipoprotein, HOMA homeostasis model assessment, hs high‑sensitivity, IFG impaired fasting glucose, IGT 
impaired glucose tolerance, IL interleukin, ISI insulin sensitivity index, LDL low‑density lipoprotein, ndT2D newly diagnosed type 2 diabetes, NGT normal glucose 
tolerance, T2D type 2 diabetes
a Individuals with known type 2 diabetes (n = 156) excluded
b Variables were  log2‑transformed for the linear regression analysis
c Individuals with anti‑hypertensive medication (n = 627) excluded
d Individuals with lipid‑lowering medication (n = 270) excluded
Table 1 continued
Variable Quarter 1 Quarter 2 Quarter 3 Quarter 4 P
IL‑1 receptor antagonist 
(pg/ml)b
344 (263; 446) 300 (235; 391) 303 (229; 379) 296 (232; 392) <0.001
Adiponectin (µg/ml)b 9.43 (6.13; 14.02) 8.68 (6.07; 13.59) 10.44 (7.37; 14.86) 11.80 (8.27; 18.08) <0.001
Table 2 Associations between SFRP5 and cardiometabolic risk factors in the KORA F4 study
Regression coefficients β and 95% CI are standardised to a doubling in SFRP5 levels in linear regression analysis. Italics print indicates significant associations (P < 0.05)
Model 1 adjusted for age, sex, Model 2 model 1 + physical activity, smoking, alcohol consumption, Model 3 model 2 + BMI, Model 4 model 3 + HDL cholesterol, LDL 
cholesterol, triglycerides, lipid‑lowering medication, hypertension, history of myocardial infarction, estimated glomerular filtration rate
a Individuals with known type 2 diabetes (n = 156) excluded
b Variables were  log2‑transformed for the linear regression analysis
c Individuals with anti‑hypertensive medication (n = 627) excluded, no adjustment for hypertension in model 4
d Individuals with lipid‑lowering medication (n = 270) excluded, no adjustment for HDL cholesterol, LDL cholesterol, triglycerides and lipid‑lowering medication in 
model 4
e No adjustment for eGFR in model 4
Variable Model 1 Model 2 Model 3 Model 4
β (95% CI) P β (95% CI) P β (95% CI) P β (95% CI) P
Fasting glucose (mmol/l)a −0.12 (−0.18; −0.06) <0.001 −0.12 (−0.18; −0.05) <0.001 −0.05 (−0.11; 0.02) 0.162 −0.06 (−0.12; 0.00) 0.061
2‑h glucose (mmol/l)a −0.33 (−0.53; −0.12) 0.002 −0.30 (−0.51; −0.10) 0.004 −0.11 (−0.32; 0.10) 0.301 −0.13 (−0.34; 0.08) 0.228
HbA1c (%)a −0.08 (−0.12; −0.05) <0.001 −0.08 (−0.12; −0.05) <0.001 −0.06 (−0.10; −0.03) 0.001 −0.07 (−0.11; −0.03) <0.001
Fasting insulin (µU/ml)a,b −0.17 (−0.29; −0.05) 0.007 −0.16 (−0.28; −0.04) 0.010 0.05 (−0.07; 0.16) 0.446 0.06 (−0.06; 0.18) 0.367
2‑h insulin (µU/ml)a,b −0.21 (−0.33; −0.09) 0.001 −0.20 (−0.31; −0.08) 0.001 −0.03 (−0.14; 0.09) 0.647 −0.03 (−0.15; 0.08) 0.571
HOMA‑IRa,b −0.20 (−0.33; −0.07) 0.002 −0.19 (−0.32; −0.06) 0.003 0.04 (−0.09; 0.16) 0.573 0.04 (−0.08; 0.16) 0.518
ISI (composite) (1/
((mmol/l) × (pmol/l)))a,b
0.25 (0.13; 0.37) <0.001 0.24 (0.12; 0.36) <0.001 0.02 (−0.09; 0.14) 0.707 0.03 (−0.09; 0.14) 0.667
HOMA‑βa −0.08 (−0.20; 0.03) 0.170 −0.08 (−0.19; 0.04) 0.206 0.08 (−0.04; 0.19) 0.207 0.09 (−0.03; 0.21) 0.126
BMI (kg/m2) −1.80 (−2.16; −1.44) <0.001 −1.77 (−2.12; −1.42) <0.001 N/A N/A −1.56 (−1.90; −1.23) <0.001
Waist circumference (cm) −4.30 (−5.21; −3.40) <0.001 −4.23 (−5.12; −3.34) <0.001 −0.27 (−0.71; 0.17) 0.229 −0.17 (−0.62; 0.28) 0.451
Systolic blood pressure 
(mmHg)c
−4.19 (−6.46; −1.92) <0.001 −3.99 (−6.28; −1.70) 0.001 −3.36 (−5.76; −0.95) 0.007 −3.40 (−5.83; −0.97) 0.006
Diastolic blood pressure 
(mmHg)c
−1.56 (−2.73; −0.40) 0.009 −1.49 (−2.67; −0.32) 0.013 −0.95 (−2.18; 0.28) 0.131 −1.07 (−2.31; 0.16) 0.089
HDL cholesterol (mmol/l)d 0.09 (0.05; 0.12) <0.001 0.08 (0.05; 0.12) <0.001 0.03 (0.00; 0.06) 0.070 0.04 (0.01; 0.08) 0.009
LDL cholesterol (mmol/l)d −0.04 (−0.13; 0.04) 0.334 −0.04 (−0.13; 0.04) 0.346 −0.06 (−0.15; 0.04) 0.229 −0.05 (−0.14; 0.04) 0.302
Triglycerides (mmol/l)b,d −0.08 (−0.15; −0.01) 0.026 −0.08 (−0.15; −0.01) 0.029 0.01 (−0.06; 0.08) 0.690 −0.02 (−0.09; 0.05) 0.646
Estimated glomerular 
filtration rate (ml/min 
per 1.73 m2)e
−2.67 (−3.80; −1.54) <0.001 −2.70 (−3.82; −1.58) 0.001 −3.74 (−4.89; −2.59) <0.001 −3.77 (−4.91; −2.63) <0.001
hsCRP (mg/l)b −0.32 (−0.45; −0.20) <0.001 −0.31 (−0.44; −0.19) <0.001 −0.16 (−0.28; −0.04) 0.012 −0.18 (−0.31; −0.06) 0.005
IL‑6 (pg/ml)b −0.13 (−0.21; −0.05) 0.001 −0.13 (−0.20; −0.05) 0.001 −0.04 (−0.12; 0.04) 0.328 −0.05 (−0.13; 0.03) 0.328
IL‑1RA (pg/ml)b −0.11 (−0.16; −0.06) <0.001 −0.11 (−0.16; −0.06) <0.001 −0.01 (−0.06; 0.04) 0.700 −0.02 (−0.07; 0.03) 0.484
Adiponectin (µg/ml)b 0.19 (0.13; 0.25) <0.001 0.19 (0.13; 0.25) <0.001 0.13 (0.06; 0.19) <0.001 0.09 (0.03; 0.15) 0.003
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hypertension), history of myocardial infarction and kid-
ney function (model 4) had almost no impact on the 
strength of the associations. In the fully adjusted model, 
higher SFRP5 levels remained associated with lower 
HbA1c, lower BMI, lower systolic blood pressure, higher 
HDL cholesterol, lower eGFR, lower hsCRP and higher 
adiponectin levels (all P ≤ 0.009).
A sensitivity analysis adjusting for waist circumfer-
ence instead of BMI yielded similar results for models 3 
and 4, but the inverse associations of SFRP5 with fasting 
glucose and with diastolic blood pressure reached signifi-
cance (P = 0.033 and P = 0.046, respectively) in the fully 
adjusted model (data not shown).
Individuals with prediabetes or type 2 diabetes (total 
n =  666) had lower SFRP5 serum levels than individu-
als with normal glucose tolerance (n =  430, P  <  0.001; 
Table 3). Logistic regression analysis showed that the odds 
of having prediabetes or diabetes was decreased by 40% 
per doubling of SFRP5 (OR [95% CI] 0.60 [0.50; 0.73], 
P  <  0.001 in both models 1 and 2 adjusting for age, sex 
and lifestyle factors). This inverse association was slightly 
attenuated by further adjustment for BMI (model 3; 
P = 0.003), but remained significant in the fully adjusted 
model 4 (OR [95% CI] 0.72 [0.58; 0.89], P  =  0.002; 
Table 3). When the group of individuals with prediabetes/
diabetes was subdivided into smaller groups of individu-
als with IFG, IGT, combined IFG/IGT, newly diagnosed 
type 2 diabetes and known type 2 diabetes, SFRP5 was 
inversely associated with the odds of IFG, IGT and known 
type 2 diabetes after full adjustment (Additional file  1: 
Table S2). In the subgroup with type 2 diabetes, neither 
glycaemic control (assessed by HbA1c), duration since the 
diagnosis of type 2 diabetes nor the type of glucose-lower-
ing medication showed any association with SFRP5 levels 
(all P > 0.05, Additional file 1: Table S3).
Discussion
This study has two main findings: (1) circulating SFRP5 
showed inverse associations with multiple risk factors 
for type 2 diabetes and cardiovascular diseases and (2) 
higher serum SFRP5 was associated with a lower odd of 
prediabetes/type 2 diabetes.
SFRP5 and type 2 diabetes
This is the first study that investigated the association 
between SFRP5, prediabetes and type 2 diabetes in a 
large population-based study and controlled for a range 
of potentially confounding factors. We extend the current 
literature by using both fasting and dynamic measures 
of insulin sensitivity. Our data shed light on the cur-
rently controversial data on SFRP5 and type 2 diabetes 
by demonstrating that higher serum SFRP5 was signifi-
cantly linked to lower odds of prediabetes/type 2 diabetes 
(as combined group of individuals with impaired glucose 
regulation) even after adjustment for age, sex, BMI, life-
style factors and risk factors for cardiovascular diseases.
Our study is in line with previous reports suggesting 
a protective role of Sfrp5 in the development of type 2 
diabetes in mice [9] and with human studies demonstrat-
ing an inverse association between circulating SFRP5 
and HOMA-IR, a fasting measure of insulin resistance 
[11–13, 15]. Additionally, two studies also reported lower 
Sfrp5 levels in patients with type 2 diabetes compared to 
individuals with normal glucose tolerance [11, 12]. How-
ever, it is in contrast to two human studies which found 
a positive [10] and no relationship [14] to HOMA-IR or 
higher Sfrp5 levels in patients with type 2 diabetes com-
pared to prediabetic individuals, although no difference 
to the group with normal glucose tolerance was observed 
[14]. Different laboratory methods cannot explain the 
observed differences because this study and the afore-
mentioned studies [10–15] used the same method to 
measure circulating SFRP5 (purchased from Cloud-
Clone, previously distributed by USCN). However, the 
previous studies were based on small sample sizes, they 
were not population-based and differed in their adjust-
ment for potential confounders. In particular the study 
with the opposing result of higher Sfrp5 levels in patients 
with type 2 diabetes was based on highly selected indi-
viduals with optimal glycaemic control (median HbA1c 
Table 3 Association between SFRP5 serum concentrations and prediabetes/type 2 diabetes
The prediabetes/type 2 diabetes group comprised all individuals with impaired fasting glucose and/or impaired glucose tolerance or with newly diagnosed or known 
type 2 diabetes. SFRP5 levels are given as median (25th; 75th percentiles) and were  log2‑transformed for the logistic regression analysis, so that OR (95% CI) refer to a 
doubling in SFRP5 levels
Model 1 adjusted for age, sex, Model 2 model 1 + physical activity, smoking, alcohol consumption, Model 3 model 2 + BMI, Model 4 model 3 + HDL cholesterol, LDL 
cholesterol, triglycerides, lipid‑lowering medication, hypertension, history of myocardial infarction, estimated glomerular filtration rate
** P < 0.01, *** P < 0.001
Group n SFRP5 levels (ng/ml) Model 1 Model 2 Model 3 Model 4
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Normal glucose tolerance 430 55.9 (42.6, 69.6) 1 1 1 1
Prediabetes/type 2 diabetes 666 48.8 (35.5, 65.7)*** 0.60 (0.50; 0.73)*** 0.60 (0.50; 0.73)*** 0.75 (0.61; 0.91)** 0.72 (0.58; 0.89)**
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5.8%) who cannot be considered representative for peo-
ple with type 2 diabetes in the general population [14].
In contrast to the majority of epidemiological studies, 
the treatment of primary human adipocytes with recom-
binant SFRP5 reduced the phosphorylation levels of 
members of the insulin signaling pathway, which would 
argue for a detrimental role of SFRP5 for insulin sensi-
tivity in these cells [26]. It may be possible that systemic 
and local effects of SFRP5 on insulin-sensitive cells are 
different, because the in vitro study concentrated on the 
impact of SFRP5 on adipocytes and did not consider the 
interaction with other cells from the adipose tissue as 
well as potential locally occurring binding partners.
SFRP5 and other cardiovascular risk factors
The occurrence of cardiovascular diseases can be an 
important consequence of type 2 diabetes. In this study, 
we also investigated the association of serum SFRP5 with 
multiple cardiovascular risk factors in addition to gly-
caemia and prediabetes/type 2 diabetes. We found that 
higher serum SFRP5 was associated with lower systolic 
and diastolic blood pressure, higher HDL cholesterol and 
lower triglycerides. All associations were independent of 
age, sex and lifestyle factors. BMI attenuated all investi-
gated relationships apart from those with systolic blood 
pressure and HDL cholesterol.
Previous findings were based on small sample sizes 
from hospital-based studies and included only people 
with Asian ethnicity with known differences in body fat 
distribution and adipokine levels compared to other eth-
nic groups. A recent hospital-based study found that cir-
culating SFRP5 was associated with a lower odds of the 
metabolic syndrome irrespective of age, sex and risk fac-
tors for cardiometabolic diseases [15]. In this study popu-
lation [15], circulating SFRP5 correlated inversely with 
systolic and diastolic blood pressure, triglycerides, free 
fatty acids and atherosclerotic index and positively with 
HDL cholesterol in a model adjusted for age and weight-
to-hip ratio. In obese children with hypertension plasma 
SFRP5 was reduced, while lifestyle intervention did not 
only improve blood pressure and BMI but also increased 
plasma SFRP5 [27]. Another study found that serum 
SFRP5 was lower in patients with coronary artery disease 
compared to controls and correlated inversely with the 
severity of the disease [13]. In mice, Sfrp5 reduced myo-
cardial infarction size and myocyte apoptosis in the heart 
after ischaemia/reperfusion injury. This might be par-
tially mediated by inhibition of pro-inflammatory effects 
of the Wnt5a/JNK signaling in macrophages [8] which 
also plays an important role in adipose tissue inflam-
mation [28] and endothelial dysfunction [29] and thus 
underlines the protective role of Sfrp5 on cardiovascu-
lar diseases. Collectively, these data demonstrate robust 
inverse associations between circulating SFRP5 and a 
range of cardiovascular risk factors in human cohorts 
using different study designs and populations, which are 
corroborated by data from animal models. However, data 
on cardiovascular outcomes are still very limited.
Interestingly, higher serum SFRP5 was associated with 
impaired renal function measured as estimated glomeru-
lar filtration rate. The link between SFRP5 and renal func-
tion has not been investigated in detail yet. One study 
reported that SFRP5 inhibited high phosphate-induced 
calcification of vascular smooth muscle cells which is a 
major cardiovascular risk factor in chronic kidney dis-
ease (CKD) [30]. However, another study showed that 
the Sfrp5 gene is hypermethylated and downregulated in 
a mouse model of CKD, whereas injection of recombi-
nant Sfrp5 inhibited Wnt signaling and attenuated renal 
fibrosis [31]. Currently, data on the association between 
SFRP5 and eGFR or albuminuria as measures of kidney 
function from other study populations are not available, 
so that further studies are required to corroborate or 
refute our finding.
SFRP5 and subclinical inflammation
One important risk factor for type 2 diabetes and its 
comorbidities is subclinical inflammation [32]. In the 
current study, we found that higher circulating SFRP5 
was associated with lower levels of the pro-inflammatory 
markers hsCRP and IL-6, and the anti-inflammatory 
protein IL-1Ra and with higher levels of adiponectin. 
BMI explained the associations between SFRP5, IL-6 
and IL-1Ra, but not those with hsCRP and adiponectin. 
It might be surprising that high SFRP5 was associated 
with lower levels of the anti-inflammatory IL-1Ra which 
argues against an anti-inflammatory action of SFRP5 at 
a first glance. However, prospective studies clearly dem-
onstrated that higher IL-1Ra levels were associated with 
a higher risk of type 2 diabetes and cardiovascular events 
[33–35]. This association may at least partially reflect a 
response to proatherogenic factors such as subclini-
cal inflammation (including IL-1β-mediated processes, 
which upregulate IL-1Ra) and oxidative stress.
Previous human cross-sectional studies supported 
the anti-inflammatory phenotype of SFRP5. They found 
that circulating SFRP5 was associated inversely with 
hsCRP, leptin, IL-6, TNFα and IL-1β and positively with 
adiponectin [12, 13, 15, 36, 37]. On the cellular level, 
the treatment with recombinant SFRP5 reduced the 
release of IL-6 by 49% in vitro in TNFα-induced primary 
human adipocytes. In that study, SFRP5 did not influ-
ence the activation of JNK, but decreased the activation 
of NFκB [26]. In obese mice Sfrp5 reduced the levels of 
the pro-inflammatory proteins TNFα, IL-6 and MCP-1 
and the content of macrophages in adipose tissue [9]. 
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Collectively, these data indicate that SFRP5 may have 
anti-inflammatory effects which could mediate the rela-
tionship between higher SFRP5 and lower cardiometa-
bolic risk.
Impact of BMI on associations between SFRP5 
and cardiometabolic risk factors
The most important confounder which influenced the 
associations between SFRP5 and risk factors for cardio-
metabolic diseases was BMI. In our study, high serum 
SFRP5 was associated with a lower BMI. This is in line 
with other human studies showing that circulating SFRP5 
associated inversely with BMI [7, 13, 15, 36] and plasma 
levels of SFRP5 were decreased in obese people [11, 
12]. Data from mouse studies reported that Sfrp5 levels 
depended on the duration of obesity. Mice fed a high-
fat diet for a short time had increased levels of Sfrp5 in 
the adipose tissue, whereas a high-fat diet for a longer 
period of time decreased levels of Sfrp5 in the adipose 
tissue [9]. In a human study, caloric restriction led to a 
fast increase of serum levels of SFRP5 [5]. So far, it is not 
known whether SFRP5 plays a physiological role as medi-
ator between BMI and obesity-associated comorbidities 
or between weight loss and an improved cardiometabolic 
risk profile.
Strengths and limitations
The large sample size and the population-based design 
allowed a valid analysis of the association between cir-
culating SFRP5 and cardiometabolic risk factors. An 
important limitation of our study is the cross-sectional 
design which precludes conclusions regarding the pre-
dictive value of circulating SFRP5 for the incidence of 
type 2 diabetes and cardiovascular events. Lower SFRP5 
levels may be cause or consequence of prediabetes/
type 2 diabetes. Our subanalyses in patients with type 
2 diabetes showed no associations between metabolic 
control or medication and SFRP5 levels, which would 
argue against hyperglycaemia as cause of lower SFRP5. 
However, one study reported an increase of SFRP5 levels 
following glucose-lowering therapy [11], so that further 
studies are required to resolve the temporal relation-
ship between changes in SFRP5 and changes in glucose 
metabolism. Additionally, participants and non-partic-
ipants in the KORA F4 study showed some differences 
in their baseline characteristics in the population-based 
KORA S4 study, but these differences were small, so that 
we have no indication for a relevant selection bias due to 
loss to follow-up. Moreover, the study is based on older 
individuals of German descent which limits the general-
isability of our observations to younger populations and 
people with different ethnic background.
Conclusion
In the population-based KORA study, circulating SFRP5 
was independently associated with BMI, HbA1c, sys-
tolic blood pressure, HDL cholesterol, eGFR, hsCRP 
and adiponectin which represent risk factors for type 2 
diabetes and diabetes-related cardiovascular diseases. 
BMI partially explained the associations between serum 
SFRP5 and cardiometabolic risk factors. However, the 
association between high SFRP5 levels with lower odds 
of prediabetes/type 2 diabetes remained significant 
after adjustment for confounders including BMI. Thus, 
SFRP5 emerges as novel biomarker that merits further 
research in the context of prevention of cardiometabolic 
diseases.
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